147 related articles for article (PubMed ID: 1442851)
1. Cardiac involvement in patients with myeloproliferative disorders.
Reisner SA; Rinkevich D; Markiewicz W; Tatarsky I; Brenner B
Am J Med; 1992 Nov; 93(5):498-504. PubMed ID: 1442851
[TBL] [Abstract][Full Text] [Related]
2. Functional and morphological cardiac changes in myeloproliferative disorders (clinical study).
Kadikoylu G; Onbasili A; Tekten T; Barutca S; Bolaman Z
Int J Cardiol; 2004 Nov; 97(2):213-20. PubMed ID: 15458686
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
Guilpain P; Montani D; Damaj G; Achouh L; Lefrère F; Le Pavec J; Marfaing-Koka A; Dartevelle P; Simonneau G; Humbert M; Hermine O
Respiration; 2008; 76(3):295-302. PubMed ID: 18160817
[TBL] [Abstract][Full Text] [Related]
4. [Heart valve involvement in systemic lupus erythematosus: an echocardiographic study].
Marcon C; Moro E; Sforza P; Piccoli G; Maresca MC; Adami A
G Ital Cardiol; 1992 Nov; 22(11):1301-8. PubMed ID: 1297616
[TBL] [Abstract][Full Text] [Related]
5. Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients.
Edoute Y; Haim N; Rinkevich D; Brenner B; Reisner SA
Am J Med; 1997 Mar; 102(3):252-8. PubMed ID: 9217593
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases.
García-Manero G; Schuster SJ; Patrick H; Martinez J
Am J Hematol; 1999 Feb; 60(2):130-5. PubMed ID: 9929105
[TBL] [Abstract][Full Text] [Related]
7. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus.
Roldan CA; Shively BK; Crawford MH
N Engl J Med; 1996 Nov; 335(19):1424-30. PubMed ID: 8875919
[TBL] [Abstract][Full Text] [Related]
8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
9. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
Dingli D; Utz JP; Krowka MJ; Oberg AL; Tefferi A
Chest; 2001 Sep; 120(3):801-8. PubMed ID: 11555513
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients.
Jindamai Y; Rattarittamrong E; Phrommintikul A; Yongsmith L; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Int J Hematol; 2020 Nov; 112(5):631-639. PubMed ID: 32700192
[TBL] [Abstract][Full Text] [Related]
11. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
12. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
13. Cardiac involvement in patients with primary antiphospholipid syndrome.
Brenner B; Blumenfeld Z; Markiewicz W; Reisner SA
J Am Coll Cardiol; 1991 Oct; 18(4):931-6. PubMed ID: 1894866
[TBL] [Abstract][Full Text] [Related]
14. Valvular heart disease in the primary antiphospholipid syndrome.
Galve E; Ordi J; Barquinero J; Evangelista A; Vilardell M; Soler-Soler J
Ann Intern Med; 1992 Feb; 116(4):293-8. PubMed ID: 1733383
[TBL] [Abstract][Full Text] [Related]
15. [The value of using transesophageal echocardiographic Doppler color flow imaging in patients undergoing cardiac valvular surgery].
Jiang L
Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Aug; 18(4):195-7, 252. PubMed ID: 2086176
[TBL] [Abstract][Full Text] [Related]
16. Value of transesophageal echocardiography as an adjunct to transthoracic echocardiography in evaluation of native and prosthetic valve endocarditis.
Pedersen WR; Walker M; Olson JD; Gobel F; Lange HW; Daniel JA; Rogers J; Longe T; Kane M; Mooney MR
Chest; 1991 Aug; 100(2):351-6. PubMed ID: 1864104
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
18. [Human valvular substitutes for the treatment of complex progressive endocarditis. Application to aortic, mitral and tricuspid valves].
Grinda JM; Jouan J; Latremouille CH; Couetil JP; Carpentier A; Fabiani JN; Deloche A
Arch Mal Coeur Vaiss; 2000 Oct; 93(10):1195-201. PubMed ID: 11107478
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic determination of the prevalence of primary myxomatous degeneration of the cardiac valves.
He Y; Guo Y; Li Z; Chen J; Kontos MC; Paulsen WH; Han J; Wang L; Gu X; Nixon JV
J Am Soc Echocardiogr; 2011 Apr; 24(4):399-404. PubMed ID: 21353473
[TBL] [Abstract][Full Text] [Related]
20. Detection of prosthetic valve strands by transesophageal echocardiography: clinical significance in patients with suspected cardiac source of embolism.
Orsinelli DA; Pearson AC
J Am Coll Cardiol; 1995 Dec; 26(7):1713-8. PubMed ID: 7594108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
